DrugPatentWatch Database Preview

Details for Patent: 9,034,867

« Back to Dashboard

Which drugs does patent 9,034,867 protect, and when does it expire?

Patent 9,034,867 protects ARISTADA and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.

Summary for Patent: 9,034,867

Title:	Pharmaceutical compositions comprising sorbitan esters
Abstract:	The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
Inventor(s):	Perry; Jason M. (Cambridge, MA), Deaver; Daniel R. (Franklin, MA), Hickey; Magall B. (Medford, MA), Remenar; Julius F. (Waltham, MA), Vandiver; Jennifer (Arlington, MA)
Assignee:	ALKERMES PHARMA IRELAND LIMITED (Dublin, IE)
Application Number:	13/423,606
Patent Claim Types: see list of patent claims	Composition; Compound; Delivery; Use;

Drugs Protected by US Patent 9,034,867

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-001	Oct 5, 2015		RX	Yes	No			Y			TREATMENT OF SCHIZOPHRENIA
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No			Y			TREATMENT OF SCHIZOPHRENIA
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes			Y			TREATMENT OF SCHIZOPHRENIA
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No			Y			TREATMENT OF SCHIZOPHRENIA

International Family Members for US Patent 9,034,867

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012231160
Australia	2017204486
Australia	2019202633
Brazil	112013023847
Canada	2830511
China	103561746
China	107252414